[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2635 followers Created: 2025-07-24 12:32:40 UTC $ATRA Atara Biotherapeutics reports FDA acceptance and priority review of Biologics License Application for Tab-celĀ® to treat EBV+ post-transplant lymphoproliferative disease. More Info: $XBI $IBB $XPH $PPH  XXX engagements  **Related Topics** [$pph](/topic/$pph) [$xph](/topic/$xph) [$ibb](/topic/$ibb) [$xbi](/topic/$xbi) [more info](/topic/more-info) [$atra](/topic/$atra) [Post Link](https://x.com/OzmosiHealth/status/1948360684540219405)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2635 followers
Created: 2025-07-24 12:32:40 UTC
$ATRA Atara Biotherapeutics reports FDA acceptance and priority review of Biologics License Application for Tab-celĀ® to treat EBV+ post-transplant lymphoproliferative disease.
More Info: $XBI $IBB $XPH $PPH
XXX engagements
/post/tweet::1948360684540219405